arrow
A

Anna Axelsson Raja

Rigshospitalet
H指数:25
被引数:2,055

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Natural History of Asymptomatic Phenotypically Mild HCM

无症状表型轻度肥厚型心肌病的自然病史

2026-07-080
PRE
Design and rationale of the EMPagliflozin after Aortic Valve Replacement (EMPAVR) study: A randomized clinical trial

EMPagliflozin在主动脉瓣置换术后研究(EMPAVR)的设计与原理:一项随机临床试验

2026-05-230
OAAI
Clinical Application of Guideline-Directed Medical Therapy in TAVR Patients With Heart Failure and Reduced Ejection Fraction

指南指导的药物治疗在合并心力衰竭及射血分数降低的TAVR患者中的临床应用

2026-01-120
PRE
Genomic and transcriptomic analyses of aortic stenosis enhance therapeutic target discovery and disease prediction

主动脉狭窄的基因组和转录组学分析可增强治疗靶点的发现和疾病预测

2025-12-190
OAAI
Follow-up of neonatally diagnosed atrial septal defects and patency of the oval foramen at preschool-age

新生儿期诊断的房间隔缺损和卵圆孔未闭学龄前随访

2025-11-140
PRE
Diagnostic yield in families to sudden cardiac death victims: a 10-year follow-up study

Gronholdt, C.L.; Hansen, B.L.; Folke, F.; Lauridsen, T.K.; Axelsson Raja, A.; Winkel, B.G.; Bundgaard, H.; Tfelt-Hansen, J.; Christensen, A.H.; Malta Hansen, C. 猝死患者家族的诊断收益:一项10年随访研究。Europace 2025, 27, euaf119. [Google Scholar] [CrossRef]

2025-07-012
OA
Valsartan and Cardiac Remodeling in Early-Stage Hypertrophic Cardiomyopathy The VANISH Randomized Clinical Trial Cardiac Magnetic Resonance Substudy

Valsartan及早期肥厚型心肌病中的心脏重塑——VANISH随机临床试验的心脏磁共振亚研究

2025-06-010
PRE
The Impact of Genotype in Dilated and Arrhythmogenic Cardiomyopathy: Insights from the SHaRE Registry

扩张型与心律失常性心肌病中的基因型影响:SHaRE注册研究的见解

2024-11-120
PRE
Valsartan and Cardiac Remodeling in Early-Stage Hypertrophic Cardiomyopathy: The VANISH Trial Cardiac Magnetic Resonance Substudy

Valsartan和早期肥厚型心肌病的心脏重塑:VANISH试验心脏磁共振亚研究

2024-11-120
PRE